When the analysis was stratified by the age at diagnosis, the RR of prostate cancer was 8.0 (95%CI 4.1–14.0) among protein-truncating BRCA2 mutation carriers diagnosed at ages <65 years. This evidence concerns the gene BRCA2 and prostate carcinoma.